Role of Surface Protein SasG in Biofilm Formation by Staphylococcus aureus

Joan A. Geoghegan, Rebecca M. Corrigan, Dominika T. Gruszka, Pietro Speziale, James P. O’Gara, Jennifer R. Potts, and Timothy J. Foster

Microbiology Department, Moyne Institute of Preventive Medicine, Trinity College, Dublin 2, Ireland; Department of Biology, University of York, York YO10 5DD, United Kingdom; Department of Biochemistry, Viale Taramelli 3/b, 27100 Pavia, Italy; UCD School of Biomolecular and Biomedical Sciences, University College Dublin, Dublin 4, Ireland; and Department of Chemistry, University of York, Heslington, York YO10 5DD, United Kingdom

Received 2 June 2010/Accepted 24 August 2010

The SasG surface protein of Staphylococcus aureus has been shown to promote the formation of biofilm. SasG comprises an N-terminal A domain and repeated B domains. Here we demonstrate that SasG is involved in the accumulation phase of biofilm, a process that requires a physiological concentration of Zn²⁺. The B domains, but not the A domain, are required. Purified recombinant B domain protein can form dimers in vitro in a Zn²⁺-dependent fashion. Furthermore, the protein can bind to cells that have B domains anchored to their surface and block biofilm formation. The full-length SasG protein exposed on the cell surface is processed within the B domains to a limited degree, resulting in cleaved proteins of various lengths being released into the supernatant. Some of the released molecules associate with the surface-exposed B domains that remain attached to the cell. Studies using inhibitors and mutants failed to identify any protease that could cause the observed cleavage within the B domains. Extensively purified recombinant B domain protein is very labile, and we propose that cleavage occurs spontaneously at labile peptide bonds and that this is necessary for biofilm formation.

Staphylococcus aureus is a commensal bacterium that is carried persistently in the anterior nares of about 20% of the human population. The organism can cause superficial skin infections, such as abscesses and impetigo, and more dangerous and potentially life-threatening invasive infections, such as endocarditis, osteomyelitis, and septic arthritis (26). Staphylococcus epidermidis and S. aureus are the major causes of infections associated with indwelling medical devices, such as central venous catheters, cardiovascular devices, and artificial joints (34, 54). The ability to form a biofilm is crucial to the microbes’ success in device-related infections. Bacteria in the biofilm matrix are in a semidormant state, are difficult to inhibit with antibiotics, and are impervious to host neutrophils and macrophages (36, 43, 44, 51). Until recently biofilm formation by staphylococci was attributed to the ability to synthesize an extracellular polysaccharide called polysaccharide intercellular adhesin (PIA), which is composed of partially deacetylated poly-N-acetylglucosamine (15, 28, 50). Attachment of bacteria to biomedical devices is mediated by adhesion to the naked plastic or metal surface by a surface component such as the major autolysin Atl (2, 14). Alternatively, adhesion to surfaces that have been conditioned by fibronectin and fibrinogen from host plasma is mediated by surface proteins such as clumping factor A (ClfA) and fibronectin binding proteins (FnBPA/B) of S. aureus or SdrG/Fbe of S. epidermidis (17, 46, 47).

Several surface proteins of staphylococci can also promote the accumulation phase of biofilm: (i) the biofilm-associated protein Bap, which is only expressed by bovine strains of S. aureus (8); (ii) the SasC surface protein of S. aureus (41); (iii) fibronectin binding proteins FnBPA and FnBPB, which are particularly associated with biofilm formation by some types of methicillin-resistant S. aureus (MRSA) (35, 48); (iv) the multifactorial virulence factor protein A, which promotes cell accumulation when expressed at high levels, for example, in mutants defective in the accessory gene regulator Agr (31); (v) the extracellular matrix binding protein (Embp) of S. epidermidis (4); (vi) the accumulation-associated protein (Aap) of S. epidermidis and the related protein SasG from S. aureus (7, 19, 40).

Aap and SasG are typical LPXTG-anchored multidomain cell-wall-associated proteins (see Fig. 1A, below). A signal sequence is removed from the N terminus during secretion across the cytoplasmic membrane. The C-terminal domains comprise a sorting signal (LPXTG) and hydrophobic membrane-spanning domain and positively charged residues that are required for covalent attachment of the proteins to cell wall peptidoglycan by sortase A. The N termini of the mature proteins (A domains) comprise related amino acid sequences that have been implicated in adhesion of bacteria to desquamated epithelial cells and could be involved in colonization of the nares and skin (7, 27, 39). The archetypal Aap protein of S. epidermidis RP62a has 12 repeats of almost identical sequences of 128 residues followed by a partial repeat of 68 residues (region B), while SasG from S. aureus strain 8325-4 and strain Newman has seven 128-residue repeats and one partial repeat. The B subunits of Aap and SasG are 64% identical.

The formation of biofilm by Aap in S. epidermidis is promoted by the removal of the A domain by cleavage by an...
as-yet-unidentified bacterial protease, an event that can also be precipitated by host proteases (40). The ability of the exposed protease to an OD 600 of 2 in PBS. Doubling dilutions (5 **10** media were added to sterile tissue culture-treated, 96-well polystyrene plates (Nunclon Delta) and incubated statically at 37°C for 24 h. Wells were washed three times with phosphate-buffered saline (PBS) and dried by inversion for 30 min. Adherent cells were stained with 0.5% (wt/vol) crystal violet, and the A**570** was measured.

For inhibition assays, DTPA, ZnCl**2**, HCl, or increasing concentrations of recombinant proteins were added to inoculated wells at the beginning of a biofilm assay, incubated, and treated as described above.

**Primary attachment assay.** Attachment assays were based on the method of Lim et al. (24). Bacteria were grown overnight in BHI medium supplemented with 1% (wt/vol) glucose, diluted in the same medium, and approximately 300 CFU in 100 **μ**l was spread on the base of empty petri dishes. Dishes were incubated upright at 37°C for 30 min, washed three times with 5 ml of sterile PBS, and covered with BHI agar. Plate counts were run in parallel, and the percent attachment was calculated. Each experiment was repeated three times. Statistical significance was determined with Student’s t test, using GraphPad software.

**Aggregation assay.** Bacteria were grown overnight in TSB and diluted to an optical density 0.600 nm (OD 600) of 1 in BHI supplemented with 1% (wt/vol) glucose. Tubes were incubated statically at 37°C for 24 h. One milliliter of broth was removed from the top of the tube, and the OD 600 was measured. The remaining culture was vortexed to resuspend the cells, and the OD 600 was measured again. The percent aggregation was calculated using the following formula: 100 × ([OD 600 of vortexed sample – OD 600 before vortexing]/OD 600 of vortexed sample). Statistical significance was determined with Student’s t test, using GraphPad software.

**Western immunoblotting.** Cell wall-associated proteins of *S. aureus* were prepared as previously described (38). Stationary-phase cultures were harvested, washed in PBS, and resuspended to an OD 40 of 40 in lysis buffer (50 mM Tris-HCl, 20 mM MgCl**2**, pH 7.5) supplemented with 30% (wt/vol) raffinose and Complete protease inhibitors (40 μg/ml; Roche). Cell wall proteins were solubilized by incubation with lysozyme (200 μg/ml; AMRL, NWK) for 10 min at 37°C. Protoplasts were removed by centrifugation at 12,000 × g for 10 min, and the supernatant containing solubilized cell wall proteins was aspirated and boiled for 5 min in Laemmli sample buffer (Sigma). To release noncovalently bound protein, cells were heated to 70°C for 10 min prior to lysostaphin digestion. For supernatant fractions, bacteria were removed from an overnight culture by centrifugation, and the supernatant was passed through a 0.2-μm filter. Where necessary, protein was concentrated by trichloroacetic acid precipitation.

Proteins were separated on 7.5% (wt/vol) polyacrylamide gels, transferred onto polyvinylidene difluoride membranes (Roche), and blocked in 10% (wt/vol) skimmed milk powder. Blots were probed with polyclonal anti-SasG A domain (1:20,000), anti-SasG B domain (1:3,000), and anti-ClfA A domain (1:5,000) antibodies. Bound antibodies were detected using horseradish peroxidase (HRP)-conjugated F(ab)2 fragments (Abcam). Reactive bands were visualized using the LumiGLO reagent and peroxide detection system (Cell Signaling Technology).

**Whole-cell immunoblotting.** SH1000(pALC2073) or SH1000(pALC2073: sausG**A** → **B**) cells were grown statically overnight and diluted 1:200 in BHI supplemented with 1% (wt/vol) glucose, RbB**2**, His (5 μM), and ZnCl**2** (5 mM). Bacteria in suspension were removed, washed twice with PBS, and resuspended to an OD 40 of 2 in PBS. Doubled dilutions (5 μl) were spotted on a nitrocellulose membrane (Protran). The membrane was blocked in 10% (wt/vol) skimmed milk proteins and probed with anti-His monoclonal antibody 7E8 (49) followed by goat anti-mouse peroxidase-conjugated F(ab)2 fragments (Abcam).

To estimate the concentration of SasG fragments in culture supernatants, bacteria were removed from an overnight culture by centrifugation and the

---

**TABLE 1. Bacterial strains**

<table>
<thead>
<tr>
<th>Strain</th>
<th>Description</th>
<th>Reference or source</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>S. aureus</em> strains</td>
<td>NCTC8325 cured of prophages</td>
<td>32</td>
</tr>
<tr>
<td>8325-4</td>
<td>Restriction-deficient mutant of 8325-4</td>
<td>23</td>
</tr>
<tr>
<td>RN4220</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SH100</td>
<td>Strain 8325-4 with repaired defect in <em>rbbB</em></td>
<td>18</td>
</tr>
<tr>
<td>SH1000 sgA</td>
<td>sgA::pAZ106 Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>18</td>
</tr>
<tr>
<td>8325-4 sgB</td>
<td>ΔsgB::Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>42</td>
</tr>
<tr>
<td>SH1000 sgB</td>
<td>sgB::Em&lt;sup&gt;+&lt;/sup&gt; transduced from 8325-4</td>
<td>This study</td>
</tr>
<tr>
<td>RN6390</td>
<td>ΔsgB::Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>37</td>
</tr>
<tr>
<td>SH1000 spl</td>
<td>ΔsgA::Em&lt;sup&gt;+&lt;/sup&gt; transduced from RN6390</td>
<td>This study</td>
</tr>
<tr>
<td>SH1000 sgA4</td>
<td>ΔsgA::Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>42</td>
</tr>
<tr>
<td>SH1000 aur</td>
<td>aur::pAZ106 Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>30</td>
</tr>
<tr>
<td>SH1000 aur/spl</td>
<td>Δaur spl::Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>3</td>
</tr>
<tr>
<td>SH1000 hsaA&lt;sub&gt;1&lt;/sub&gt; hsaA&lt;sub&gt;2&lt;/sub&gt;</td>
<td>hsaA&lt;sub&gt;1&lt;/sub&gt;::Em&lt;sup&gt;+&lt;/sup&gt; hsaA&lt;sub&gt;2&lt;/sub&gt;::Tc&lt;sup&gt;+&lt;/sup&gt;</td>
<td>Unpublished</td>
</tr>
<tr>
<td>8325-4 atl</td>
<td>Δatl::Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>11</td>
</tr>
<tr>
<td>SH1000 atl</td>
<td>atl::Em&lt;sup&gt;+&lt;/sup&gt; transduced from 8325-4</td>
<td>This study</td>
</tr>
<tr>
<td>SA113</td>
<td>Restriction-deficient</td>
<td>20</td>
</tr>
<tr>
<td>SA113 aaa</td>
<td>aaa::Em&lt;sup&gt;+&lt;/sup&gt;</td>
<td>13</td>
</tr>
<tr>
<td>125</td>
<td>Clinical isolate s8</td>
<td>9</td>
</tr>
<tr>
<td>207</td>
<td>Clinical isolate s15</td>
<td>9</td>
</tr>
<tr>
<td>410</td>
<td>Clinical isolate s15</td>
<td>9</td>
</tr>
<tr>
<td>3093</td>
<td>Clinical isolate s15</td>
<td>9</td>
</tr>
<tr>
<td>L. lactis MG1363</td>
<td>Plasmid-free derivative of strain NCTC 712</td>
<td>52</td>
</tr>
<tr>
<td>S. epidermidis strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TU3298</td>
<td>Transformable strain</td>
<td>1</td>
</tr>
<tr>
<td>CSF4198</td>
<td>Cerebrospinal fluid isolate, biofilm positive</td>
<td>5</td>
</tr>
<tr>
<td><em>S. aureus</em> strains</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5'-GGGAGATCTGGGCGAAAAAAGACATAACAGAATTAG-3′</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5'-GGGAGATCTGGGCGAAAAAAGACATAACAGAATTAG-3′</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
supernatant was passed through a 0.2-μm filter. Doubling dilutions of supernatant (5 μl) or rA-His (1 to 20 nM; 5 μl) were spotted on a nitrocellulose membrane (Protran). The membrane was blocked in 10% (wt/vol) skimmed milk proteins and probed with anti-SasG A domain antibodies (1:20,000) followed by HRP-conjugated protein A (1:500, Sigma).

Expression and purification of recombinant proteins. Plasmid pQE30/unGA*-38 expresses N-terminal hexahistidine-tagged SasG A domain protein. Plasmid pQE30/unGE*-38 (39) expresses His-tagged SasG B protein (two full and one partial B domain). Plasmid pQE30/unGE*-Gm was digested with BamHI and HindIII to release DNA specifying the B domains, and this was cloned into the pGEX-KG vector to give pGEX-KG SasGm, expressing glutathione S-transferase (GST)-tagged B domains (rB2.5-GST). Plasmid pC4F4 expresses His-tagged Cia N23 domains (33). E. coli strain XL-1 Blue (Stratagene) was used as the host for selecting recombinant plasmids following cloning, and E. coli strain TOP3 (Stratagene) was used for expression of recombinant proteins. The codon-optimized sequence of a single SasG B domain was synthesized (GenScript Corporation) and subcloned into the pSPK2 vector, employing NdeI and BamHI restriction sites, to give pSPK2-B. A single SasG B domain was expressed with an N-terminal hexahistidine tag in E. coli BL21-Gold(DE3) (Stratagene).

Recombinant His-tagged proteins were expressed and purified by nickel affinity chromatography as described previously (33). To obtain untagged single B domain protein, the N-terminal hexahistidine tag was removed using human rhinovirus (HRV) 3C protease (Promega). GST-tagged protein was purified as described previously (33). Highly purified protein was obtained by passing the protein through an anion exchange column following affinity chromatography. Untagged SasG B domain protein was obtained by treating rB2.5-GST with thrombin to remove the GST tag and passing this through a GST-Trap column (GE Healthcare), followed by a benzamidine column (GE Healthcare) to remove GST and thrombin.

Surface plasmon resonance. Surface plasmon resonance (SPR) was performed using the BLAcore X100 system (GE Healthcare). Goat anti-GST IgG (30 μg/ml; GE Healthcare) was diluted in 10 mM sodium acetate buffer at pH 5.0 and immobilized on CMS sensor chips using amine coupling. This was performed using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, followed by N-hydroxysuccinimide and ethanolamine hydrochloride, as described by the manufacturer. rB2-GST (100 μg/ml) in PBS was passed over the anti-GST surface of one flow cell while recombinant GST (100 μg/ml) was passed over the other flow cell to provide a reference surface. rB-His (4 μM) in PBS or in PBS with ZnCl2 (10 mM) was flowed over the surface at a rate of 5 μl/min. All sensorgram subtraction was performed using the BIAevaluation software (Biacore). The response generated from injection of buffer over the chip was also subtracted from all sensorgrams.

SEC-MALLS. The size exclusion chromatography-multiangular light scattering (SEC-MALLS) experiment was performed using a Superdex 75 HR10/30 column (GE Healthcare) and Shimadzu high-performance liquid chromatography system. Data for a single recombinant B domain protein were collected in the presence of EDTA (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM EDTA) and zinc acetate (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 5 mM ZnAc2). Samples (100 μl) of protein at a concentration of 100 μM were loaded onto a gel filtration column and eluted with one column volume (24 ml) of appropriate running buffer at a flow rate 0.5 ml/min. The eluting fractions were monitored using a Dawn HELEOS-II 18-angule light-scattering detector (Wyatt Technologies), an SPD20A UV/Vis detector (Shimadzu), and an Optilab rEX refractive index monitor (Wyatt Technologies). Recorded data were analyzed using Astra (Wyatt Technologies).

RESULTS

Role of SasG in the accumulation phase of biofilm formation. Expression of SasG by laboratory strains such as SH1000 and Newman could not be detected by Western blotting. However, SasG is expressed at high levels by many clinical isolates (7). Expression of SasG by S. aureus SH1000 has been achieved by placing the sasG gene under the control of the P_xyl/tetO promoter (P_xyl/tetO). Tetracycline-inducible promoter of the pALC2073 vector (7), Boles and Horswill (3) previously reported that S. aureus strain SH1000 forms biofilms independently of PIA, and our previous work showed that biofilm formation by SH1000 (pALC2073/sasG+) did not require PIA. SasG-mediated biofilm formation occurred in a manner that was dependent on the inducer concentration and also on the length of the SasG protein (7). Here, the role(s) of SasG in the primary attachment and the cell accumulation phases of biofilm formation was examined. Expression of SasG did not increase the adherence of bacteria to polystyrene (67% for SH1000[pALC2073]) and 64% for SH1000[pALC2073::sasG-]) compared with SH1000(pALC2073) (P = 0.0234). This suggests that SasG plays a role in the accumulation phase but not the primary attachment phase of biofilm formation.

Identification of the region of SasG responsible for biofilm formation. Variants of SasG comprising only the B region or the SasG A domain linked to the repeated regions of SdrF (B-repeats and serine-aspartate repeat regions) were expressed in SH1000 to give SH1000(pALC2073/sasG+ A‘ B‘) and SH1000(pALC2073/sasG+ A‘ B‘) respectively. SdrF is anchored on the surface of S. epidermidis, has C-terminal repeat regions of a similar length to the B region of SasG, and these were used as spacers between the A domain of SasG and the bacterial cell surface.

Whole-cell immunoblotting with anti-SasG A domain and anti-SasG B repeat antibodies was employed to quantify the level of expression of SasG by SH1000 (pALC2073/sasG+ A‘ B‘) and SH1000(pALC2073/sasG+ A‘ B‘). Similar expression levels of the SasG A domain were detected from SH1000(pALC2073/sasG+ A‘ B‘) and SH1000 (pALC2073/sasG+) (Fig. 1B). However, expression of the B domains from SH1000(pALC2073/sasG+ A‘ B‘) was approximately 2-fold lower than from SH1000(pALC2073/sasG+). To achieve equal levels of expression, tetracycline (90 ng/ml) was added to SH1000(pALC2073/sasG+ A‘ B‘) to increase expression from the P_xyl/tetO promoter. The integrity of the constructs was validated by Western immunoblotting analysis of protein solubilized from the cell wall during stable protoplast formation (cell wall extracts) and detected with anti-SasG A domain and anti-SasG B domain antibodies (data not shown).

Each strain was tested for biofilm formation. SH1000 (pALC2073/sasG+) and SH1000(pALC2073/sasG+ A‘ B‘), strains that express the B region of SasG, formed robust biofilms, whereas SH1000(pALC2073/sasG+ A‘ B‘) and SH1000 (pALC2073/sdrF+) did not (Fig. 1C). This provides evidence that the B repeat region of SasG and not the A domain is responsible for biofilm formation.

Inhibition of biofilm formation by recombinant SasG domains. To further investigate a role for the B repeat region in SasG-mediated biofilm formation, increasing concentrations of recombinant hexahistidine-tagged A domain (rA-His) or rB2.5-His protein (comprising two full and one partial B repeat) were added to bacterial cultures at the beginning of the biofilm assay. The rB2.5-His protein inhibited biofilm formation in a dose-dependent manner, whereas rA-His had no effect (Fig. 2). A single B domain (rB-His) also inhibited biofilm formation (data not shown). This provides further evidence that the B repeat region of SasG is responsible for biofilm formation.

Several clinical isolates that express SasG (7) can form bio-
films. In the case of strains 207 and 3093, biofilms could be inhibited by the addition of rB2.5-His (data not shown). This demonstrated that SasG is likely to promote biofilms in these strains. Strains 125 and 410 formed a biofilm that was not inhibited by rB2.5-His (data not shown). It is possible that SasG does not mediate biofilm formation in these strains and that PIA or another surface protein is responsible. The addition of rB2.5-His had no effect on biofilm formation by the Aap-expressing S. epidermidis isolate CSF41498. This strain reportedly forms protein-dependent biofilms (5, 16). Either a surface protein other than Aap is responsible or the SasG B domains are not sufficiently similar to Aap B domains to bind and cause inhibition.

The effect of zinc chelation on SasG-mediated biofilm formation. Previous studies demonstrated the necessity of Zn2+ for biofilm formation by staphylococci (6). The zinc chelator DTPA inhibited biofilm formation by S. epidermidis RP62a and community-associated MRSA USA300. Biofilm formation by USA300 isolates is unlikely to be mediated by SasG, as the sasG gene contains a nonsense mutation that precludes expression of the full-length protein (10). To determine if zinc chelation could inhibit SasG-mediated biofilm formation, the effect of DTPA was tested. Biofilm formation by SH1000 (pALC2073sasG/H11001A/H11002B/H11001) was reduced in a manner that was dependent on the concentration of DTPA (Fig. 3). Zinc chelation had no effect on the attachment of SH1000 to polystyrene (data not shown). Biofilm was restored by the addition of ZnCl2. Furthermore, the concentration of Zn2+ present in the BHI broth used for biofilm formation was measured by inductively coupled plasma-mass spectroscopy and found to be 4.8 μM, very close to the concentration in human plasma (10.7 to 18.3 μM) (21). These data illustrate that Zn2+ is required at physiologically relevant concentrations for SasG-mediated biofilm formation.

Recombinant B domain interactions in Zn2+. The B domains of Aap form dimers in the presence of ZnCl2 (6). The B domains of SasG share 64% amino acid identity with Aap B domains, and SasG-mediated biofilm formation was inhibited by zinc chelation (Fig. 3). Therefore, the ability of SasG B domains to interact in a Zn2+-dependent manner was tested using SPR and SEC-MALLS. A recombinant protein comprising two full and one partial SasG B domain was expressed in E. coli.
coli with an N-terminal GST affinity tag (rB<sub>2.5</sub>-GST). Recombinant B<sub>2.5</sub>-GST was captured on the surface of a sensor chip that had been coated with a polyclonal anti-GST antibody. A tag-free recombinant protein (rB<sub>2.5</sub>) was generated by cleaving the GST tag from rB<sub>2.5</sub>-GST. When rB<sub>2.5</sub> was passed over the surface of the rB<sub>2.5</sub>-GST-coated chip, no interaction could be detected (Fig. 4A). However, in a solution of ZnCl<sub>2</sub>, rB<sub>2.5</sub> bound to the rB<sub>2.5</sub>-GST-coated chip (Fig. 4A). Similar behavior was observed for a single recombinant B domain (molecular mass, 14,501.2 g/mol) using SEC-MALLS. Molar masses calculated for the major species eluted from a gel filtration column revealed that in the absence of divalent cations the B domain is monomeric (15,150 ± 1,212 g/mol), while in the presence of ZnAc<sub>2</sub>, it forms dimers (29,840 ± 2,026 g/mol) (Fig. 4B). Both SPR and SEC-MALLS data demonstrate that SasG B domains are capable of associating and that this interaction is Zn<sup>2+</sup>-dependent.

**Cellular localization of SasG.** Western immunoblotting of proteins from the cell wall of SH1000(pALC2073::sasG<sup>A</sup> B<sup>+</sup>) grown under planktonic culture conditions solubilized by lyso- staphin revealed a dominant band of 220 kDa that was presumed to correspond to full-length SasG (predicted molecular mass of 190 kDa) and several smaller bands that were also recognized by anti-SasG A domain antibodies (Fig. 5A). A similar cleavage pattern was noted for proteins isolated from the cell wall of bacteria that were derived from a biofilm (data not shown). This suggests that SasG undergoes limited cleavage within the B repeat region. The bands differed in molecular mass by 18 to 22 kDa, the approximate size of one B domain, suggesting that there are two cleavage sites in each B domain.

The covalent anchoring of SasG to the bacterial cell wall is catalyzed by the sortase A enzyme, which recognizes an LPKTG sorting motif at the C terminus of the protein. If the protein is cleaved within the B region, then only the full-length form of the protein should be linked to the cell wall and be detectable in cell wall extracts when probed with anti-A domain antibodies. All other A domain-containing fragments should be released into the supernatant. However, as shown above, SasG fragments of different sizes were detected in cell wall extracts by anti-SasG A domain antibodies. One explanation is that cleaved SasG fragments have become attached noncovalently to the cell wall.

To investigate this, SH1000(pALC2073::sasG<sup>A</sup> B<sup>+</sup>) cells were heated to 70°C in order to promote the release of noncovalently bound proteins. The anti-SasG A domain antibodies recognized proteins of different sizes in the cell wall fraction of control unheated cells (Fig. 5A). In contrast, anti-A domain antibodies only recognized the full-length protein in the cell wall fractions of cells that had been heated to 70°C, indicating that truncated A domain-containing fragments were noncovalently bound and had been released. The fragments appeared to have undergone proteolysis within the SasG A domain upon release from the cell. This may suggest that heating cells to 70°C releases and/or activates a cell surface-associated protease that degrades the SasG A domain.

Anti-SasG B domain antibodies recognized proteins of different sizes in cell wall extracts of heated and nonheated cells (Fig. 5A). This revealed that some of the SasG B domain-containing fragments are covalently associated with the cell wall. Fragments of different sizes were released from cells that had been heated to 70°C, implying that some fragments containing SasG B-repeats are associated noncovalently with the cell wall. These experiments suggest that SasG fragments containing an A domain and various numbers of B domains are associated noncovalently with the cell wall. ClfA served as a control for a typical covalently anchored cell wall protein. No protein was released by heating to 70°C, and no difference was seen between cells that had or had not been heated (Fig. 5A).

SasG fragments of different lengths and showing the characteristic cleavage pattern were also detected in culture supernatants by anti-SasG A domain and anti-SasG B domain antibodies (Fig. 5B). This shows that fragments of SasG are being released from the cell and cleaved during growth of the culture and not during lysisstaphin treatment.

Given that recombinant B domains inhibit SasG-mediated biofilm formation, it is possible that released fragments of SasG are inhibitory. The concentration of SasG present in the culture supernatant of SH1000(pALC2073::sasG<sup>A</sup> B<sup>+</sup>) cells was estimated by whole-cell dot immunoblotting with anti-SasG A domain antibodies and compared to that for a known concentration of rA-His. Comparing the intensity of the dots allowed the concentration of SasG in the culture supernatant to be estimated at 10 nM (data not shown). A much higher concentration of rB<sub>2.5</sub>-His (31.25 nM) was required to inhibit biofilm formation by 20% (Fig. 2). Thus, it is unlikely that released fragments of SasG reach a high enough concentration to inhibit the formation of biofilm.

**Binding of SasG B domains to SasG-expressing cells.** Given the ability of SasG rB-repeats to dimerize in the presence of Zn<sup>2+</sup>, it seemed possible that released SasG fragments were reattaching noncovalently to exposed SasG B-repeats on the cell surface. To test this hypothesis, rB<sub>2.5</sub>-His was added to BHI broth prior to inoculation with SH1000(pALC2073) or SH1000(pALC2073::sasG<sup>A</sup> B<sup>+</sup>). After growth, cells were washed and probed with a monoclonal antibody to the His<sub>6</sub> tag in whole-cell immunoblot assays. rB<sub>2.5</sub>-His did not bind detect-
ably to SH1000(pALC2073). rB2.5-His bound to SH1000(pALC2073) when ZnCl₂ was present in the growth medium (Fig. 5C). This illustrates that SasG B domains can bind to the cell surface-expressed SasG B region. It also strongly suggests that released SasG B domain-containing fragments reassociate with the bacteria surface by attaching to exposed cell wall-anchored B-repeats in a Zn²⁺-dependent manner. Furthermore, this demonstrates that SasG B domains do not associate with any other cell surface component.

Investigating the role of proteolysis in the cleavage of SasG. It is possible that SasG is cleaved by a protease during growth. Aap, the SasG homologue from S. epidermidis, must be proteolytically cleaved at a site close to the C terminus of the A domain to allow biofilm formation (40). The cleavage of SasG in S. aureus is different and occurs within the B domains. To try to identify the S. aureus protease responsible, SH1000(pALC2073sasG⁺) was grown in the presence of various protease inhibitors. A recent study demonstrated that a combina-
tion of the protease inhibitors E-64, 1,10-phenanthroline, and dichloroisocoumarin reduced protease activity of S. aureus strain UAMS-1 (45). However, protease inhibitors used either singly or in combination had no effect on the cleavage of SasG (data not shown). Similarly, commercially available protease inhibitor cocktails did not inhibit the cleavage of SasG. Previously it was reported that the broad-spectrum protease inhibitor α2-macroglobulin prevented SasG-mediated biofilm formation (7). However, cell wall extracts of bacteria grown in α2-macroglobulin had the same SasG cleavage profile as those grown in its absence (data not shown). Interestingly, addition of α2-macroglobulin to a suspension of SH1000 (pALC2073sasG\(^+\)) cells inhibited aggregation (41% compared to 81%), suggesting that its effect is mediated by binding to the cell surface and preventing accumulation rather than inhibiting protease activity.

Expression of SasG by protease-deficient mutants was tested. Strains deficient in each of the known extracellular proteases and in the membrane-bound proteases HtrA\(_1\) and HtrA\(_2\) were examined after introduction of pALC2073sasG\(^+\). Protease-deficient strains showed similar SasG cleavage patterns compared to SH1000(pALC2073sasG\(^+\)) (data not shown). SH1000 aur spl has very low levels of extracellular protease activity (3), but expression of SasG in this host exhibited the same pattern of cleavage as in the wild type (data not shown). In addition, each of the protease-deficient strains carrying pALC2073sasG\(^+\) formed biofilm at levels similar to SH1000(pALC2073sasG\(^+\)) (data not shown). Strains defective in the autolysins Atl and Aaa were also tested. Once again no difference in the SasG cleavage profile was observed (data not shown). SH1000 atl(pALC2073sasG\(^-\)) failed to form biofilm, but this was attributed to a reduced level of attachment to the polystyrene plates [67% for SH1000(pALC2073sasG\(^+\)) and 32% for SH1000 atl(pALC2073sasG\(^+\)); \(P = 0.032\)], in agreement with previous studies demonstrating a role for Atl in the primary attachment phase of biofilm formation (2). Taken together these results indicate that none of the known extracellular proteases is responsible for the cleavage of SasG and that HtrA\(_1\)/HtrA\(_2\) and autolysins Atl and Aaa can also be excluded.

**Cleavage during secretion.** SasG must be cleaved within the B region either during or after secretion to account for cleaved fragments being present in the supernatant and on the cell surface. Truncates formed by intracellular cleavage would lack an N-terminal signal sequence and would not pass through the Sec secretion system. The possible role of membrane-bound enzymes was investigated. S. aureus expresses two membrane-bound sortases. Sortase A anchors surface proteins containing LPXTG motifs to cell wall peptidoglycan. Sortase B is only expressed under iron-limiting conditions and is responsible for anchoring a single surface protein, IsdC, via an NPQTN sorting motif. Examination of the amino acid sequence of a SasG B domain revealed the presence of two sequences resembling sortase cleavage motifs (NPETG and NPKTG). It seemed possible that SasG could be cleaved at these sequences to a limited degree by sortase during secretion. To test this hypothesis, bacteria were grown in the presence of the sortase inhibitor E-64, which reduced the amount of cell wall-bound SasG, resulting in elevated levels of SasG being released into the culture supernatant. However, the same pattern of cleavage of SasG occurred, suggesting that sortases do not play a role in the cleavage of the B region of SasG (Fig. 6A).

Next, pALC2073sasG\(^-\) was expressed in an srtA mutant. SasG failed to be sorted while cleaved SasG was evident in the culture supernatant, supporting the conclusion that sortase A has no role in the cleavage of SasG B domains (Fig. 6B). An
elevated level of SasG protein was detected in the supernatant of the srtA mutant. We conclude that this is due to (i) the failure of SasG to be anchored to the cell wall and (ii) the inability of released SasG fragments to reattach to the cell surface in the absence of surface-bound SasG B domains.

Another possibility was that the SasG protein was being cleaved to a limited degree during secretion by the Sec pathway. The membrane-bound signal peptidase SpsB cleaves AXA consensus motifs in the signal sequence of proteins passing through the Sec secretory system. The spsB gene is essential in S. aureus. SpsB is resistant to all common protease inhibitors. A peptide inhibitor of SpsB (NIFKPST peptide) inhibits SpsB activity at concentrations that cause a small reduction in growth of SH1000 (22). SH1000(pALC2073sasG/H11001) was grown in media containing concentrations of NIFKPST peptide that were subinhibitory to growth. However, no reduction in cleavage of SasG was observed, indicating that the SpsB peptidase is not responsible for the processing of SasG within the B region (Fig. 6C).

Next, SasG was expressed in L. lactis(pKS80::sasG+) and S. epidermidis(pALC2073sasG+) to investigate whether cleavage occurs in other Gram-positive hosts. The same pattern of SasG cleavage was noted, suggesting that the same mechanism of cleavage occurs in these organisms (Fig. 6D). In addition, L. lactis expressing SasG showed increased aggregation [66% for L. lactis(pKS80::sasG+) compared to 38% for L. lactis(pKS80); P = 0.031], illustrating that the expression of SasG is sufficient to promote accumulation during biofilm formation.

DISCUSSION

We previously reported that the S. aureus surface protein SasG promotes biofilm formation independently of PIA (7). This study set out to investigate the molecular basis of SasG-mediated biofilm formation. SasG was found to play a role in the accumulation phase but not the primary attachment phase of biofilm formation. Variants of SasG comprising only the A or B domains were expressed on the surface of S. aureus. The region of SasG responsible for biofilm formation was localized to the B region, with the A domain playing no role. This was confirmed by the ability of recombinant domain B but not A to inhibit biofilm formation.

Previous studies demonstrated the requirement for Zn2+ in biofilm formation by staphylococci (6). Here, Zn2+ chelation inhibited SasG-mediated biofilm formation, and Zn2+ was required at concentrations found in plasma for biofilm formation to occur. Conrady et al. (6) proposed that Zn2+-dependent Aap B domain dimerization on the staphylococcal surface represents the basis of biofilm formation by S. epidermidis RP62a.
This study on SasG further supports this hypothesis. SasG B domains, like Aap B domains, form dimers in ZnCl₂. Furthermore, recombinant B domain protein bound to the surface of cells expressing SasG B region, demonstrating that B domain oligomerization occurs on the cell surface. This is the first direct evidence that B domain interactions occur on the cell surface. These interactions likely mediate cell accumulation in biofilm formation.

The interaction between recombinant B domain protein and surface-bound SasG B region was only detected when Zn²⁺ was added to the growth medium. The reason for this is likely to be due to the addition of a high concentration of recombinant B protein reducing the concentration of Zn²⁺ in the medium. Thus, more Zn²⁺ must be added to allow biofilm formation.

Western immunoblotting of proteins solubilized from the cell wall by lysozyme revealed that SasG is cleaved into several fragments. The cleavage is limited and occurs within the B region. SasG fragments could be released from cells by heating, indicating that some are attached to the cell surface in a noncovalent manner. Attachment most likely occurs following release of cleaved SasG into the medium by B domain dimerization on the cell surface. This was demonstrated directly by the binding of recombinant B domain protein to the surface of cells expressing the B domain of SasG. We postulated that a secreted or cell envelope-associated protease was responsible for the limited cleavage of SasG B domains. However, cleavage of SasG could not be prevented by adding protease inhibitors to the growth medium. Furthermore, strains deficient in extracellular proteases and the membrane-bound HtrA proteases showed the same pattern of SasG cleavage. This implies that proteases may not be responsible for cleavage of SasG. SasG is cleaved in the B region in contrast to the S. aureus surface protein Bap, which is degraded by the extracellular metalloprotease aureolysin and the serine protease SspA in a sigB mutant and loses the ability to promote biofilm formation (29). Strains defective in the autolysins Atl and Aaa showed no difference in the SasG cleavage profile. The same pattern of SasG cleavage also occurred in L. lactis and S. epidermidis, indicating that the same mechanism of cleavage is responsible. Failure to identify a protease responsible for SasG processing could indicate that more than one protease can mediate cleavage or that the protease is resistant to protease inhibitors. Alternatively, spontaneous cleavage at labile bonds in the SasG B domain could occur. This is supported by the observation that recombinant B domain protein that had been extensively purified was cleaved during incubation in buffer at 37°C. Spontaneous cleavage of peptide bonds promoted by arginine occurs during processing of the EscU protein of E. coli and the YscU protein of Yersinia enterocolitica at a consensus motif, NPTH (53). A similar mechanism may occur here.

We propose a model for SasG-mediated biofilm formation by S. aureus (Fig. 8). Initially, the full-length SasG protein is covalently attached to the cell wall by sorting. Limited cleavage of SasG within the B region occurs during growth. SasG fragments of different lengths are released into the supernatant, and some fragments reattach to exposed B domains on the cell surface in a noncovalent manner that is dependent on Zn²⁺. The cleaved and exposed SasG B domains on neighboring cells interact with each other in a Zn²⁺-dependent manner, leading to cell accumulation and biofilm formation.

We believe that SasG must be cleaved either during or after secretion to account for cleaved fragments being present both in the supernatant and on the cell surface. Truncated forms created by cleavage intracellularly would lack an N-terminal signal sequence and would not pass through the Sec secretion system. If a protease is responsible for the processing of SasG, it was not identified using mutants, and the cleavage of SasG could not be inhibited by any protease inhibitor. The inability to inhibit cleavage of SasG prevents us from determining if this event is required for biofilm formation. In the case of Aap, the SasG homologue from S. epidermidis, proteolysis within the A domain has been shown to be a prerequisite for biofilm formation (40). The identity of the S. epidermidis protease is also unknown. We propose that cleavage of SasG is also necessary for biofilm formation to occur. While the cleavage of Aap and SasG occurs at different sites, the effect is the same: the A domain is removed, leaving B domains exposed on the surface.

S. aureus is a major cause of infections associated with indwelling medical devices. It will be of interest to determine if SasG-promoted biofilm formation contributes to virulence in animal models of foreign body infection. The fibronectin binding proteins FnBPA and FnBPB enhance colonization of catheters in mouse models of foreign body infection, while the absence of the ica operon has no effect (48). This suggests that surface proteins can mediate biofilm formation in vivo.

ACKNOWLEDGMENTS

This work was funded by a Science Foundation Ireland Programme Investigator grant (to T.J.F.). J.R.P. and D.T.G. thank the British Heart Foundation for financial support. This work was also supported by grants from the Health Research Board (to J.P.O.) and Fondazione CARIPLO “Vaccines 2009-3546” (to P.S.).

We thank the Centre for Microscopy and Analysis (Trinity College Dublin) for carrying out inductively coupled plasma-mass spectroscopy and A. Loughman and M. Tallant (Trinity College Dublin) for assistance with plasmid construction.


